A Prospective, Randomized, Parallel-Controlled, Double-Blind, Double-Dummy, Multicenter, Phase III Clinical Trial of Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Latest Information Update: 09 Aug 2024
At a glance
- Drugs Icaritin (Primary) ; Huachansu
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms BESTPOP
- Sponsors Beijing Shenogen Biomedical
Most Recent Events
- 06 Feb 2023 Status changed from not yet recruiting to recruiting.
- 28 Oct 2022 New trial record